AntonyDavidLoebelMD

Psychiatry • Larchmont, NY

Physician

Join to view full profile

Dr. Loebel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Loebel's full profile

Already have an account?

Office
36 Harrison Dr
Larchmont, NY 10538
Phone+1 914-833-1493

Education & Training

Zucker School of Medicine at Hofstra/Northwell at Zucker Hillside HospitalResidency, Psychiatry, 1986 - 1990
University of Washington School of MedicineClass of 1986

Certifications & Licensure

NY State Medical License 1989 - 2025
American Board of Psychiatry and Neurology Psychiatry

Publications & Presentations

PubMed

4 citations
Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy.
Francesca Perini, Jadwiga Maria Nazimek, Shane Mckie, Liliana P Capitão, Jessica Scaife
Schizophrenia. 2023-08-07
5 citations
A multicenter, double-blind, placebo-controlled, randomized, Phase 1b crossover trial comparing two doses of ulotaront with placebo in the treatment of narcolepsy-cata...
Steven T Szabo, Seth C Hopkins, Robert Lew, Antony Loebel, Thomas Roth
Sleep Medicine. 2023-07-01
2 citations
The Effect of Lurasidone on Anxiety Symptoms in Patients With Bipolar Depression: A Post Hoc Analysis.
Joseph F Goldberg, Cynthia Siu, Michael Tocco, Andrei Pikalov, Antony Loebel
The Journal of Clinical Psychiatry. 2023-06-07

Authored Content

Clinical Relevance Versus Statistical Significance: DelBello and Colleagues Respond to EditorialApril 2018
Efficacy and Safety of Lurasidone in Children and Adolescents with Bipolar I Depression: A Double-Blind, Placebo-Controlled StudyOctober 2017
Efficacy and Safety of Lurasidone in Children and Adolescents with Bipolar I Depression: A Double-Blind, Placebo-Controlled StudyOctober 2017

Press Mentions

Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization CollaborationSeptember 30th, 2021
Sunovion Pens $890M Otsuka Pact for a Clutch of Neuropsychiatric DrugsSeptember 30th, 2021
NeuroPace Launches Epilepsy Platform to Personalize Seizure CareAugust 4th, 2021
Join now to see all